Skip to main content

Table 3 Unpaired t-test results comparing multiple features (including patient age, tumor volume, and numerous tissue parameter comparisons) for the 22 'benign' tumors and the 14 'malignant' tumors

From: A prospective pilot clinical trial evaluating the utility of a dynamic near-infrared imaging device for characterizing suspicious breast lesions

Parameter Tissue type Mean ± standard deviation P value
Age (years) Benign/malignant 44.0 ± 13.9/57.6 ± 13.6 0.006
Tumor volume (cm3) Benign/malignant 1.0 ± 0.9/1.4 ± 0.7 0.13
Tumor tissue [StO2] – baseline (%) Benign/malignant 87.9 ± 10.1/89.9 ± 6.8 0.51
Tumor tissue [Hbt] – baseline (μM) Benign/malignant 11.0 ± 6.0/11.0 ± 7.0 0.77
Reference tissue [StO2] – baseline (%) Benign/malignant 92.4 ± 5.3/93.5 ± 6.5 0.57
Reference tissue [Hbt] – baseline (μM) Benign/malignant 8.0 ± 4.0/9.0 ± 5.0 0.74
Differential [StO2] – baseline (%) Benign/malignant -6.1 ± 10.0/-4.1 ± 3.3 0.47
Differential [Hbt] – baseline (%) Benign/malignant 12.1 ± 32.3/17.8 ± 19.7 0.56
Tumor [StO2] contrast – baseline (%) Benign/malignant 4.1 ± 4.6/2.8 ± 1.2 0.34
Tumor [Hbt] contrast – baseline (%) Benign/malignant 16.6 ± 8.1/13.2 ± 9.7 0.27
Reference tissue [StO2] contrast – baseline (%) Benign/malignant 2.3 ± 1.1/2.3 ± 1.2 0.88
Reference tissue [Hbt] contrast – baseline (%) Benign/malignant 11.7 ± 5.6/14.4 ± 8.7 0.27
Differential [StO2] contrast – baseline (%) Benign/malignant 1.7 ± 4.1/0.5 ± 1.4 0.32
Differential [Hbt] contrast – baseline (%) Benign/malignant 4.8 ± 6.3/-1.2 ± 6.2 0.008
Tumor tissue [StO2] – compression peak (%) Benign/malignant 87.2 ± 11.4/88.6 ± 7.8 0.7
Tumor tissue [Hbt] – compression peak (μM) Benign/malignant 10.0 ± 6.0/11.0 ± 7.0 0.58
Reference tissue [StO2] – compression peak (%) Benign/malignant 91.4 ± 6.9/92.2 ± 7.6 0.76
Reference tissue [Hbt] – compression peak (μM) Benign/malignant 7.0 ± 4.0/8.0 ± 5.0 0.62
Differential [StO2] – compression peak (%) Benign/malignant -6.2 ± 12.8/-4.2 ± 4.7 0.59
Differential [Hbt] – compression peak (%) Benign/malignant 13.0 ± 33.7/22.6 ± 22.1 0.35
Tumor [StO2] contrast – compression peak (%) Benign/malignant 4.3 ± 4.2/3.6 ± 2.8 0.56
Tumor [Hbt] contrast – compression peak (%) Benign/malignant 16.4 ± 7.9/14.0 ± 12.5 0.48
Reference [StO2] contrast – compression peak (%) Benign/malignant 2.8 ± 1.4/2.8 ± 2.2 0.97
Reference [Hbt] contrast – compression peak (%) Benign/malignant 12.2 ± 6.1/16.7 ± 13.9 0.18
Differential [StO2] contrast – compression peak (%) Benign/malignant 1.6 ± 3.4/0.8 ± 1.7 0.45
Differential [Hbt] contrast – compression peak (%) Benign/malignant 4.3 ± 6.3/-2.7 ± 6.8 0.004
Variation in differential [StO2] (%) Benign/malignant 0.1 ± 4.5/0.2 ± 2.1 0.96
Variation in differential [Hbt] (%) Benign/malignant -0.9 ± 12.0/-4.9 ± 8.3 0.29
Variation in differential [StO2] – tumor (%) Benign/malignant -0.3 ± 1.4/-0.8 ± 2.1 0.41
Variation in differential [Hbt] – tumor (%) Benign/malignant 0.2 ± 4.2/-0.8 ± 5.2 0.54
Variation in differential [StO2] – reference (%) Benign/malignant -0.4 ± 0.6/-0.5 ± 1.3 0.79
Variation in differential [Hbt] – reference (%) Benign/malignant -0.4 ± 3.5/-2.3 ± 5.9 0.24
Differential variations of [StO2] – compression peak (%) Benign/malignant 0.1 ± 1.7/-0.3 ± 1.2 0.44
Differential variations of [Hbt] – compression peak (%) Benign/malignant 0.6 ± 4.7/1.5 ± 4.4 0.57
  1. [Hbt], total hemoglobin concentration; [StO2], tissue blood oxygen saturation.
  2. Significant P values are italicized.